IL267195A - - Google Patents

Info

Publication number
IL267195A
IL267195A IL26719519A IL26719519A IL267195A IL 267195 A IL267195 A IL 267195A IL 26719519 A IL26719519 A IL 26719519A IL 26719519 A IL26719519 A IL 26719519A IL 267195 A IL267195 A IL 267195A
Authority
IL
Israel
Application number
IL26719519A
Other languages
English (en)
Other versions
IL267195B2 (en
IL267195B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL267195A publication Critical patent/IL267195A/en
Publication of IL267195B1 publication Critical patent/IL267195B1/en
Publication of IL267195B2 publication Critical patent/IL267195B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL267195A 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder IL267195B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
IL267195A true IL267195A (enExample) 2019-07-31
IL267195B1 IL267195B1 (en) 2024-01-01
IL267195B2 IL267195B2 (en) 2024-05-01

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267195A IL267195B2 (en) 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Country Status (14)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CA (1) CA3046297A1 (enExample)
CL (1) CL2019001618A1 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12070448B2 (en) * 2018-09-21 2024-08-27 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
US20220117941A1 (en) * 2018-09-21 2022-04-21 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
US20230000763A1 (en) * 2019-11-22 2023-01-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1154489C (zh) * 1997-08-14 2004-06-23 弗·哈夫曼-拉罗切有限公司 抗神经学疾病的杂环乙烯基醚
JP2004520263A (ja) * 2000-07-21 2004-07-08 テバ ファーマシューティカル インダストリーズ リミティド 双極性障害における躁病を治療するためのバルプロ酸および2−バルプロエン酸アミド誘導体の使用
BR0207832A (pt) 2001-02-27 2004-06-22 Ortho Mcneil Pharm Inc Compostos de carbamato para uso na prevenção ou tratamento de distúrbio bipolar
CN1250215C (zh) * 2001-02-27 2006-04-12 奥索-麦克尼尔药品公司 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
MX2009004798A (es) * 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
CA2765566C (en) 2009-06-22 2016-04-12 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
ES2791186T3 (es) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Triazoles como inhibidores de receptores NR2B

Also Published As

Publication number Publication date
CA3046297A1 (en) 2018-06-21
KR102635938B1 (ko) 2024-02-13
AU2017374458A1 (en) 2019-07-04
CN110290788A (zh) 2019-09-27
BR112019011930A2 (pt) 2019-10-29
MY199104A (en) 2023-10-13
US20190314337A1 (en) 2019-10-17
EP3556366A1 (en) 2019-10-23
ZA201903747B (en) 2021-01-27
JP7208139B2 (ja) 2023-01-18
CL2019001618A1 (es) 2019-08-23
JP2020502106A (ja) 2020-01-23
WO2018111008A1 (ko) 2018-06-21
EP3556366B1 (en) 2025-10-22
RU2019121913A (ru) 2021-01-15
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
KR20190087572A (ko) 2019-07-24
US11571410B2 (en) 2023-02-07
RU2019121913A3 (enExample) 2021-04-21
IL267195B1 (en) 2024-01-01
AU2017374458B2 (en) 2023-03-02
MX2019006940A (es) 2019-09-06

Similar Documents

Publication Publication Date Title
BR112019008128A2 (enExample)
IL267195A (enExample)
BR202016021516U2 (enExample)
BR202016016457U2 (enExample)
CN303538889S (enExample)
CN303537447S (enExample)
CN303537758S (enExample)
CN303537406S (enExample)
CN303536656S (enExample)
CN303536638S (enExample)
CN303536567S (enExample)
CN303536519S (enExample)
CN303536482S (enExample)
CN303536426S (enExample)
CN303537591S (enExample)
CN303538954S (enExample)
CN303536360S (enExample)
CN303536266S (enExample)
CN303655250S (enExample)
CN303536246S (enExample)
CN303536216S (enExample)
CN303537770S (enExample)
CN303536130S (enExample)
CN303536127S (enExample)
CN303537771S (enExample)